ArticleOphthalmology and therapy2025
Safety Evaluation of Bilateral Same-Day Intravitreal Injection of Faricimab.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIntravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is the most commonly performed ophthalmic procedure. Many retinal specialists routinely perform same-day bilateral intravitreal anti-VEGF injections, in order to reduce the burden to patient and clinic time. There are several reports demonstrating the safety of bilateral same-day treatment with ranibizumab, bevacizumab, and aflibercept, but currently, there are no reports regarding faricimab. The purpose of this study is to report safety outcomes in a cohort of patients who received bilateral same-day faricimab intravitreal injections.
methodsThis is a retrospective observational study that included patients who received bilateral same-day faricimab and had a follow-up of at least 6 months. All patients were treated by 4 monthly faricimab injections as a loading dose and subsequently followed up at monthly intervals. All intravitreal injections were done in a sterile room and the second injection was treated as a separate procedure.
resultsOne hundred eyes from 50 patients were included in the study. The mean follow-up period was 7 months, during which a total of 487 intravitreal injections of faricimab were done. During the follow-up period, five patients (10%) presented with minor ophthalmic issues. There were no cases of endophthalmitis and no patients reported a cerebrovascular, cardiovascular, or thromboembolic event.
conclusionsOur study showed that bilateral same-day intravitreal injection of faricimab appeared to be well tolerated in this limited cohort and is the preferred approach in our practice. Larger studies with longer follow-up will be required in order to support our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.